Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a single... | March 8, 2022
The first class Biosimulation market report works upon a number of industry and market parameters including latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights and innovation. An explicit marke...
Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Oppenheimer issued their FY2026 earnings per share estimates for Compugen in a report released on Friday, February 25th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.65) per share for the year. Oppenheimer has a “Outperform” rating and a […]
Compugen (NASDAQ:CGEN – Get Rating) had its target price decreased by Oppenheimer from $17.00 to $14.00 in a research note published on Friday, Analyst Price Targets reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Compugen’s FY2026 earnings at ($0.65) EPS. A number of other brokerages have […]